Retinal Vein Occlusion - Pipeline Review, H2 2017 - Research and Markets
Thursday, 07 December 2017 07:06
Dec. 7, 2017 17:09 UTC

Retinal Vein Occlusion - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)-- The "Retinal Vein Occlusion - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Retinal Vein Occlusion - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and

discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and

Error. Page cannot be displayed. Please contact your service provider for more details. (10)

Unknown stages are 3, 3, 3, 9, 2 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and

tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Retinal Vein Occlusion - Overview
  3. Retinal Vein Occlusion - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Retinal Vein Occlusion - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Retinal Vein Occlusion - Companies Involved in Therapeutics Development
  • Acucela Inc
  • Addmedica SAS
  • Aerpio Therapeutics Inc
  • Annexin Pharmaceuticals AB
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical Inc
  • Formycon AG
  • Graybug Vision Inc
  • Kala Pharmaceuticals Inc
  • Lupin Ltd
  • Mabion SA
  • Novartis AG
  • Ocular Therapeutix Inc
  • Ohr Pharmaceutical Inc
  • Regeneron Pharmaceuticals Inc
  • SciFluor Life Sciences LLC
  • ThromboGenics NV

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs

Source: Research and Markets

BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!